EIPICO continues to make unprecedented results since the beginning of this year, despite of the nowadays global difficulties , such as rising energy prices , supply chain problems which are not only raising prices but also disappearing many goods as well as Covid-19 effects.
Dr. Ahmed Kelani EIPICO Chairman & Managing Director stated Till 30 September, EIPICO made total sales more than 2.4 EGP billion with 17 % growth.
Dr. Kelani add " IQVIA data refers to remarkable growth by EIPICO in September by 298 million EGP sales, 97 % growth (twice sales than September 2020) achieving 42 % growth in the first 9 months of 2021 which is 7 times of the market growth "
Also , EIPICO at the top of all Egyptian Pharmaceutical companies in the local market by unit wise , from beginning of this year & in September as well.
With 81% growth & 8.4% market share in September, while local units' sales declined by -2 % , Achieving 134 sales of million unit from Jan. till Sep.
Dr. Kelani referred EIPICO has 8 products of the best-selling 100 Pharmaceutical products by units in Egypt for example , (CETAL No. 2 at the list, CEFOTAX No.3 at the list and EPICEPHEN...),
also EIPICO made a sales' large progress on many governorates and territories in Egypt.
EIPICO's ophthalmic products – as other EIPICO's products - are doctors trusted cause of EIPICO keen on providing The most efficient & quality medicines with affordable price, that ensures ranked number 1 for EIPICO's ophthalmic products in units in September and since the beginning of the year by 92% growth which is 5 times the market growth,
With 28% market share in September and total sales 15 million unit, that is make EIPICO ranked number 3 for ophthalmic products best-selling by value with 137 % growth for the same month.
EIPICO has 4 products from the best-selling 10 ophthalmic products by units in Egypt since the beginning of the year
Which are (DEXATROL the best-selling ophthalmic product in Egypt, DEXATOBRIN, TOBRIN, NOSTAMINE).
Despite of EIPICO is the ranked number 1 in the local market's sold units' numbers and ophthalmic , In the same time it is ranked No. 7 of the by value in the local market with 3.6 % market share and ranked No.3 in ophthalmics, in value in September , because EIPICO's products are of the most lowest prices , highest quality & efficient in the market .
This assures our commitment towards working in accordance with the state's strategy and ACDIMA- the state's strong arm for providing medicines and taking imminent actions eradicating any crisis arises .
Dr. Kelani added that EIPICO kept its outstanding performance in pharmaceutical export during the first nine months this year by 26 % growth in exports from September 2020 with total exports of 35.8 $ million ( 563 million EGP ) EIPICO is capturing 22 % of total Egyptian exports, exporting to 70 Countries around the world and exporting 25 % of its products which are more than 250 million unit of 400 pharmaceutical products with 2457 million EGP.
These indictors and achievements prove that, our strategic and short plans for development and investment in Egypt or our common projects abroad, are running according to multi field studies with the highest standards of professionalism and specialization. Moreover they don’t disrupt our first commitment towards providing medicines for citizens .
As we previously declared, approving to assign the modular structure building of EIPICO 3 project for manufacturing Biologicals & Biosimilars to the Swedish company " Pharmadul Morimatsue " 43.5 $ million cost and project investments around 1.2 Bellion EGP.
Dr. Kelani concluded “ We affirm our commitment towards providing medicines for citizens and in Egypt or worldwide , it is a honor to be proud of and duty seeking to”
I thank all EIPICO'S -5000- employees for this performance, because they are successful partners.
It worth to mention that EIPICO was established in Tenth of Ramadan City in 1980, with a capital of 7 EGP million, currently raised to 1500 EGP million, 991.705 million EGP paid capital ,started production in 1985 .
On 130,000 m² (Factory 1 over 90,00 m², Factory 2 over 30,00 m² and EIPICO 3 over 10,500 m² - construction's steps have been started).